View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 9, 2021

LoA Update: Cytokinetics’ omecamtiv mecarbil transition to next development stage in paediatric heart failure drops by six points after Amgen decoupling

Cytokinetics’ omecamtiv mecarbil in Phase I paediatric heart failure had its Phase Transition Success Rate (PTSR) drop by six points to 65% despite no change in its Likelihood of Approval (LoA) of 5%.

By Reynald Castañeda

Cytokinetics’ omecamtiv mecarbil in Phase I paediatric heart failure had its Phase Transition Success Rate (PTSR) drop by six points to 65% despite no change in its Likelihood of Approval (LoA) of 5%. The update happened on 1 June, on the back of Amgen officially terminating its collaboration with Cytokinetics in developing the asset, effective 20 May.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The decoupling between Cytokinetics and Amgen was first announced in November 2020, with the former to develop omecamtiv mecarbil independently or with another partner in the future.

LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. LoA is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Cytokinetics has a $1.60bn market cap, while Amgen’s is $136.28bn.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy